Ligand specificity, privileged substructures and protein druggability from fragment-based screening
- PMID: 21411360
- DOI: 10.1016/j.cbpa.2011.02.020
Ligand specificity, privileged substructures and protein druggability from fragment-based screening
Abstract
Fragment-based screening has now become an established method for the generation of lead molecules against therapeutic targets. Fragment molecules are simple, low molecular-weight compounds with few chemical functionalities. These characteristics lead to high hit rates for fragment screening as compared to the more classical High-Throughput Screening of drug-like molecules and raise the question of the specificity of fragment molecules. This review analyzes recent outcomes of fragment screenings published in the literature, showing that the specificity of the fragments can be related to their structures and physico-chemical properties. We also discuss both the concept of privileged fragment scaffolds and the role of fragment-based screening in predicting protein druggability, highlighted by recent publications in the field.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
Efficiency of hit generation and structural characterization in fragment-based ligand discovery.Curr Opin Chem Biol. 2011 Aug;15(4):482-8. doi: 10.1016/j.cbpa.2011.06.008. Epub 2011 Jul 1. Curr Opin Chem Biol. 2011. PMID: 21724447 Review.
-
Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.Methods Enzymol. 2011;493:469-85. doi: 10.1016/B978-0-12-381274-2.00018-2. Methods Enzymol. 2011. PMID: 21371602
-
Recent progress in fragment-based lead discovery.Curr Opin Pharmacol. 2009 Oct;9(5):615-21. doi: 10.1016/j.coph.2009.04.009. Epub 2009 May 27. Curr Opin Pharmacol. 2009. PMID: 19477685 Review.
-
Design and implementation of an ribonucleic acid (RNA) directed fragment library.J Med Chem. 2009 Jun 25;52(12):3753-61. doi: 10.1021/jm9000659. J Med Chem. 2009. PMID: 19445516
-
Fragment-based ligand discovery.Mol Interv. 2009 Feb;9(1):22-30. doi: 10.1124/mi.9.1.7. Mol Interv. 2009. PMID: 19299661 Review.
Cited by
-
LSA: a local-weighted structural alignment tool for pharmaceutical virtual screening.RSC Adv. 2019 Jan 29;9(7):3912-3917. doi: 10.1039/c8ra08915a. eCollection 2019 Jan 25. RSC Adv. 2019. PMID: 35518105 Free PMC article.
-
Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.Eur J Med Chem. 2013 Apr;62:498-507. doi: 10.1016/j.ejmech.2013.01.023. Epub 2013 Jan 26. Eur J Med Chem. 2013. PMID: 23416191 Free PMC article.
-
New Frontiers in Druggability.J Med Chem. 2015 Dec 10;58(23):9063-88. doi: 10.1021/acs.jmedchem.5b00586. Epub 2015 Aug 11. J Med Chem. 2015. PMID: 26230724 Free PMC article.
-
Genetic Approaches to Facilitate Antibacterial Drug Development.Cold Spring Harb Perspect Med. 2015 Feb 13;5(7):a021139. doi: 10.1101/cshperspect.a021139. Cold Spring Harb Perspect Med. 2015. PMID: 25680982 Free PMC article. Review.
-
Virtual and biophysical screening targeting the γ-tubulin complex--a new target for the inhibition of microtubule nucleation.PLoS One. 2013 May 15;8(5):e63908. doi: 10.1371/journal.pone.0063908. Print 2013. PLoS One. 2013. PMID: 23691113 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources